Skip to main content

Table 3 GI symptoms in relation to genotype in patients with TTR mutations

From: THAOS: Gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease

Symptom V30M Non-V30M p value
n = 792 n = 252
Any GI symptom 547 (69.3%) 130 (56.0%) <0.001
Early satiety 242 (30.7%) 44 (19.0%) <0.001
Nausea 150 (19.0%) 35 (15.1%) 0.172
Vomiting 125 (15.8%) 22 (9.5%) 0.016
Constipation 178 (22.6%) 41 (17.7%) 0.117
Diarrhea/constipation 225 (28.6%) 42 (18.1%) 0.001
Diarrhea 174 (22.1%) 42 (18.2%) 0.199
Fecal incontinence 57 (7.2%) 11 (4.8%) 0.186
Unintentional weight loss 272 (34.6%) 70 (30.3%) 0.224
  1. Number of patients, n (%), reporting gastrointestinal (GI) symptoms at enrollment. The TTR V122I, I68L and L111M mutations (mainly associated with cardiac complications) were excluded from the non-V30M group.